The oversubscribed seed round was co-led by firstminute Capital and Playfair to support product expansion and international growth.
"Instead of yet another freelancer platform that simply digitizes transactions that could and would happen without it, Passionfruit is bringing a completely new workforce to the market. Gen Z will represent 27% of the global workforce by 2025 and it has been so inspiring to see our specialists as they say goodbye to the Victorian-age structure of the 9-5, and begin a new life working on their own terms. Better still, companies love working with them this way. Smart businesses are realizing that there’s a more elastic and efficient way to manage their relationship with talent."
Seedcamp led the oversubscribed round alongside existing investors IQ Capital and Playfair Capital.
"Our studio has naturally wanted to transition over the years into being worldbuilding-led so it could not be better timing seeing a new audience emerge that is looking for immersive game-like experiences where they own parts of the universes they love. At Cauldron we have a history of working in markets where we know our art and emotive storytelling can have a dramatic impact and we are seeing the rising base of Web3 players yearning for more."
Playfair Capital led the seed investment in Qureight, with backing from Meltwind, Ascension, and Cambridge Angels, to accelerate drug development partnerships.
"our next targets are pulmonary hypertension and adverse drug effects in complex lung cancer patients. This funding will allow us to use our platform to work with our biopharma partners to accelerate drug development in these areas."
The financing was led by Brighteye Ventures with participation from Playfair and RLC.
"In founding Skiller Whale, I wanted to offer CTOs a real alternative to hiring for skill gaps. This means the kind of learning that has a ~100% completion rate, gives people immediately usable skills, and guarantees that nobody wastes a single hour learning something they already know."
The financing round was led by Talis Capital with participation from multiple angels and existing backers.
"We are delighted to have received such credible investor support to continue on our mission to empower and support those with cancer. It’s imperative that we start understanding how therapies are affecting patients: for pharmaceutical companies, our technology enables deeper patient understanding which leads to better drugs, greater differentiation and faster licensing, as well as the ability to provide personalised scalable support to patients. For patients, this means better care and improved outcomes from cancer. We’re now looking forward to applying our rich data and machine learning capabilities to novel predictive analytics to generate even richer insights for our life science partners."
